XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities    
Net income $ 843.7 $ 1,837.4
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 59.9 26.8
Right-of-use asset impairment, net of broker fees 0.0 24.8
Equity-based compensation 85.1 79.6
Non-cash performance allocations and incentive fees (89.8) (1,703.9)
Non-cash principal investment income (365.1) (303.8)
Other non-cash amounts (11.9) 5.5
Consolidated Funds related:    
Realized/unrealized (gain) loss on investments of Consolidated Funds 248.1 (102.8)
Realized/unrealized (gain) loss from loans payable of Consolidated Funds (227.4) 93.1
Purchases of investments by Consolidated Funds (1,984.2) (2,700.4)
Proceeds from sale and settlements of investments by Consolidated Funds 1,637.0 2,426.9
Non-cash interest income, net (4.5) (6.7)
Change in cash and cash equivalents held at Consolidated Funds (82.9) (8.3)
Change in other receivables held at Consolidated Funds 10.6 (99.5)
Change in other liabilities held at Consolidated Funds (31.2) 365.1
Purchases of investments (456.8) (103.4)
Proceeds from the sale of investments 287.1 398.2
Payments of contingent consideration (5.7) (49.9)
Changes in deferred taxes, net 55.9 481.9
Change in due from affiliates and other receivables (65.3) (14.9)
Change in deposits and other (7.1) (26.6)
Change in accounts payable, accrued expenses and other liabilities (67.2) 25.4
Change in accrued compensation and benefits (372.1) (113.9)
Change in due to affiliates 2.8 24.5
Change in lease right-of-use assets and lease liabilities (4.6) 4.6
Change in deferred revenue (12.9) 35.6
Net cash provided by (used in) operating activities (558.5) 595.3
Cash flows from investing activities    
Purchases of fixed assets, net (17.4) (17.6)
Purchase of CBAM intangibles and investments, net (618.4) 0.0
Proceeds from sale of MRE, net of cash sold 0.0 5.9
Net cash used in investing activities (635.8) (11.7)
Cash flows from financing activities    
Issuance of 4.625% subordinated notes due 2061, net of financing costs 0.0 484.2
Payments on CLO borrowings (9.0) (229.4)
Proceeds from CLO borrowings, net of financing costs 41.1 87.7
Net borrowings (payments) on loans payable of Consolidated Funds 405.9 (15.9)
Dividends to common stockholders (207.1) (177.4)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 166.9 44.4
Distributions to non-controlling interest holders (156.6) (42.9)
Common shares issued for performance allocations 36.5 0.0
Common shares repurchased (105.3) (25.0)
Change in due to/from affiliates financing activities (27.7) 12.8
Net cash provided by financing activities 75.9 69.7
Effect of foreign exchange rate changes (46.9) (25.7)
Increase (decrease) in cash, cash equivalents and restricted cash (1,165.3) 627.6
Cash, cash equivalents and restricted cash, beginning of period 2,475.1 989.6
Cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2
Supplemental non-cash disclosures    
Net asset impact of deconsolidation of Consolidated Funds 0.0 (34.4)
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 1,308.9 1,586.2
Restricted cash 0.9 31.0
Total cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2
Cash and cash equivalents held at Consolidated Funds 230.7 187.5
Consolidated Operating Entities    
Cash flows from operating activities    
Net income 814.0 1,837.2
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 59.9 26.8
Right-of-use asset impairment, net of broker fees 0.0 24.8
Equity-based compensation 85.1 79.6
Non-cash performance allocations and incentive fees (94.6) (1,703.9)
Non-cash principal investment income (318.4) (313.3)
Other non-cash amounts (11.9) 5.5
Consolidated Funds related:    
Purchases of investments (470.3) (161.3)
Proceeds from the sale of investments 298.2 418.5
Payments of contingent consideration (5.7) (49.9)
Changes in deferred taxes, net 55.9 481.9
Change in due from affiliates and other receivables (64.8) (14.8)
Change in deposits and other (7.1) (26.6)
Change in accounts payable, accrued expenses and other liabilities (67.2) 25.4
Change in accrued compensation and benefits (372.1) (113.9)
Change in due to affiliates 2.8 24.5
Change in lease right-of-use assets and lease liabilities (4.6) 4.6
Change in deferred revenue (12.9) 35.6
Net cash provided by (used in) operating activities (113.7) 580.7
Cash flows from investing activities    
Purchases of fixed assets, net (17.4) (17.6)
Purchase of CBAM intangibles and investments, net (618.4) 0.0
Net cash used in investing activities (635.8) (11.7)
Cash flows from financing activities    
Issuance of 4.625% subordinated notes due 2061, net of financing costs 0.0 484.2
Payments on CLO borrowings (9.0) (229.4)
Proceeds from CLO borrowings, net of financing costs 41.1 87.6
Dividends to common stockholders (207.1) (177.4)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 4.4 7.4
Distributions to non-controlling interest holders (36.6) (22.9)
Common shares issued for performance allocations 36.5 0.0
Common shares repurchased (105.3) (25.0)
Change in due to/from affiliates financing activities (27.8) 12.8
Net cash provided by financing activities (372.6) 68.5
Effect of foreign exchange rate changes (43.2) (9.9)
Increase (decrease) in cash, cash equivalents and restricted cash (1,165.3) 627.6
Cash, cash equivalents and restricted cash, beginning of period 2,475.1 989.6
Cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2
Supplemental non-cash disclosures    
Issuance of common shares related to the acquisition of CBAM intangibles and investments 194.5 0.0
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 1,308.9 1,586.2
Restricted cash 0.9 31.0
Total cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2
Cash and cash equivalents held at Consolidated Funds $ 230.7 $ 187.5